Loading clinical trials...

Efficacy, Tolerability and Safety of LAS41004 Formulations in a Psoriasis Plaque Test | Clinical Trials | Clareo Health

COMPLETEDPHASE1/PHASE2

Efficacy, Tolerability and Safety of LAS41004 Formulations in a Psoriasis Plaque Test

A Randomized, Controlled, Observer-blind Psoriasis Plaque Test to Investigate the Anti-psoriatic Efficacy, Tolerability and Safety (Skin Atrophy) of LAS41004 Formulations in Patients With Mild to Moderate Plaque Psoriasis

NCT02111499•Almirall, S.A.

View on ClinicalTrials.gov

Summary

Clinical investigation of anti-psoriatic efficacy and atrophy

Detailed Description

In this trial three concentrations of bexarotene in combination with a fixed concentration of betamethasone dipropionate, as well as monotherapy with bexarotene, will be investigated regarding their efficacy, tolerability and safety in patients with mild to moderate plaque psoriasis and will be compared with the vehicle and an active comparator. Since a side effect of the application of corticosteroids is skin atrophy, additionally three non-lesional test areas (not affected by psoriasis) on the volar forearm will be treated with the active reference product, one of the fixed combinations and the vehicle. Skin atrophy will be investigated by visual assessment and ultrasound at these test areas

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•18 to 75 years of age
•Men and women with skin type I to IV (Fitzpatrick 1974).
•Suffering from mild to moderate plaque psoriasis of at least 6 months duration that is amenable to local therapy.
•With at least one stable psoriatic plaque in an area sufficient for product application meeting the following criteria:
•* Located at the trunk and/or the extremities (plaques located on the head, palms, or soles of the feet, intertriginous or genitoanal areas are not suitable).
•* Plaques with a clinical score of the parameter erythema and or induration of ≥ 2 for each sign at the screening visit. At Day 1 each parameter has to be scored ≥ 2.
•* Where more than one plaque is to be used, plaques should be comparable, with at least "2" in each score for erythema and induration.
•* • Body surface area (BSA) involvement \< 10 %.
•Prepared to give written informed consent specific to the trial, before any assessment is performed.
•• In the case of women of childbearing potential using reliable methods of contraception which result in a low failure rate i.e. less than 1% per year (e.g. contraceptive implants or injectables, combined oral contraceptives, some intrauterine devices, sexual abstinence or vasectomized partner). During the study an additional barrier method (e.g. condoms) should be used. Non-childbearing potential is defined as surgical sterilization (hysterectomy, ovariectomy or tubal ligation), postmenopausal status (continuous amenorrhea of at least 2 years).
+1 more criteria

Exclusion Criteria

•• Patients who need systemic treatment for their psoriasis.
•* Severe forms of psoriasis or forms of psoriasis other than chronic plaque psoriasis,
•* Systemic treatment (see table below):
•Corticosteroids, antibiotics 4 weeks prior to trial Day 1 and during conduct of trial Retinoids Ciclosporin Methotrexate Fumaric acid esters 3 months prior to trial Day 1 and during conduct of trial Anti-inflammatory substances, NSAIDs 2 weeks prior to trial Day 1 and during conduct of trial Biologics 6 months prior to trial Day 1 and during conduct of trial
•Topical treatment of all other body regions with corticosteroids or immunosuppressants where more than 20 % of the body surface area is treated.
•Diseases:
•Significant skin infections caused by bacteria, viruses or fungi, including but not limited to tuberculosis, syphilis or varicella zoster infection Parasitic infections

Locations (1)

proDERM GmbH

Schenefeld, Schleswig-Holstein, Germany

Key Dates

Start Date

March 1, 2014

Primary Completion Date

May 1, 2014

Completion Date

June 1, 2014

Last Updated

June 9, 2014

Enrollment

ACTUAL participants

Conditions

Psoriasis

Interventions

LAS41004-IMP1

DRUG

LAS41004 IMP2

DRUG

LAS41004 IMP3

DRUG

LAS41004 IMP4

DRUG

LAS41004 IMP6

DRUG

LAS41004 IMP5

DRUG

A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis

NCT07449234

Psoriasis

View study

RECRUITINGPHASE3

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

NCT07116967

Plaque Psoriasis

View study

RECRUITINGPHASE3

A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis

NCT07250802

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 9, 2014Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Efficacy, Tolerability and Safety of LAS41004 Formulations in a Psoriasis Plaque Test

Inclusion Criteria

Exclusion Criteria

A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis

An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis

Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis

Real-Life Evaluation of Guselkumab Dosing Interval Adjustments